Publications
2015
. A phase 1/2 open-label study of safety and antitumor activity of EPI-506, a novel AR N-terminal domain inhibitor, in men with metastatic castration-resistant prostate cancer (mCRPC) with progression after enzalutamide or abiraterone. ASCO Annual Meeting 2016. J Clin Oncol 33, 2015 (suppl; abstr TPS5072)
Read More >
2014
. N-terminal targeting of androgen receptor variant enhances response of castration resistant prostate cancer to taxane chemotherapy. Mol Oncol 2014
Read More >. Characterization of niphatenones that inhibit androgen receptor N-terminal domain. PLoS One 2014
Read More >
2013
. An androgen receptor N-terminal domain antagonist for treating prostate cancer. J Clin Invest 2013
Read More >. Spongian diterpenoids inhibit androgen receptor activity. Mol Cancer Ther 2013
Read More >